Open Access
Issue
Med Buccale Chir Buccale
Volume 22, Number 2, avril 2016
Page(s) 119 - 122
Section Cas clinique et revue de la littérature / Up-to date review and case report
DOI https://doi.org/10.1051/mbcb/2016006
Published online 23 February 2016
  1. Jones WA, Gerrie J, Pritchard J. Cherubism--familial fibrous dysplasia of the jaws. J Bone Joint Surg Br 1950;32-B:334-347. [Google Scholar]
  2. Reichenberger EJ, Levine MA, Olsen BR, Papadaki ME, Lietman SA. The role of SH3BP2 in the pathophysiology of cherubism. Orphanet J Rare Dis 2012;7 Suppl 1:S5. [CrossRef] [PubMed] [Google Scholar]
  3. Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001;28:125-126. [CrossRef] [PubMed] [Google Scholar]
  4. Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T, et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011;147:1340-1354. [CrossRef] [PubMed] [Google Scholar]
  5. Ueki Y, Lin C-Y, Senoo M, Ebihara T, Agata N, Onji M, et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 « cherubism » mice. Cell 2007;128:71-83. [CrossRef] [PubMed] [Google Scholar]
  6. Colombo F, Cursiefen C, Neukam FW, Holbach LM. Orbital involvement in cherubism. Ophthalmology 2001;108:1884-1888. [CrossRef] [PubMed] [Google Scholar]
  7. Raposo-Amaral CE, de Campos Guidi M, Warren SM, Almeida AB, Amstalden EMI, Tiziane V, et al. Two-stage surgical treatment of severe cherubism. Ann Plast Surg 2007;58:645-651. [CrossRef] [PubMed] [Google Scholar]
  8. Kalantar Motamedi MH. Treatment of cherubism with locally aggressive behavior presenting in adulthood: report of four cases and a proposed new grading system. J Oral Maxillofac Surg 1998;56:1336-1342. [CrossRef] [PubMed] [Google Scholar]
  9. Chomette G, Auriol M, Guilbert F, Vaillant JM. Cherubism. Histo-enzymological and ultrastructural study. Int J Oral Maxillofac Surg 1988;17:219-223. [CrossRef] [Google Scholar]
  10. Barthélémy I, Mondié J-M. Giant cell tumors and pseudogiant cell tumors of the jaws. Rev Stomatol Chir Maxillofac 2009;110: 209-213. [CrossRef] [PubMed] [Google Scholar]
  11. Silva GCC, Gomez RS, Vieira TC, Silva EC. Cherubism: long-term follow-up of 2 patients in whom it regressed without treatment. Br J Oral Maxillofac Surg 2007;45:567-570. [CrossRef] [PubMed] [Google Scholar]
  12. Katz JO, Dunlap CL, Ennis RL. Cherubism: report of a case showing regression without treatment. J Oral Maxillofac Surg 1992; 50:301-303. [CrossRef] [PubMed] [Google Scholar]
  13. Zachariades N, Papanicolaou S, Xypolyta A, Constantinidis I. Cherubism. Int J Oral Surg 1985;14:138-145. [CrossRef] [PubMed] [Google Scholar]
  14. Shah N, Handa KK, Sharma MC. Malignant mesenchymal tumor arising from cherubism: a case report. J Oral Maxillofac Surg 2004;62:744-749. [CrossRef] [PubMed] [Google Scholar]
  15. Abela S, Cameron M, Bister D. Orthodontic treatment in cherubism: an overview and a case report. Aust Orthod J 2014; 30:214-220. [PubMed] [Google Scholar]
  16. Dewan K, Bishop K. Management of a patient suffering with Cherubism with dental implants. Eur J Prosthodont Restor Dent 2011;19:67-71. [PubMed] [Google Scholar]
  17. Khojasteh A, Sadr SJ, Saboury A, Shidfar S. Onlay bone augmentation and bilateral open sinus lifting with simultaneous implant placement in a cherubic patient. J Craniofac Surg 2014; 25:193-196. [CrossRef] [Google Scholar]
  18. Meng X-M, Yu S-F, Yu G-Y. Clinicopathologic study of 24 cases of cherubism. Int J Oral Maxillofac Surg 2005;34:350-356. [CrossRef] [PubMed] [Google Scholar]
  19. Koury ME, Stella JP, Epker BN. Vascular transformation in cherubism. Oral Surg Oral Med Oral Pathol 1993;76:20-27. [CrossRef] [PubMed] [Google Scholar]
  20. Souter MA, Bird PA, Worthington JP. Giant cell reparative granuloma of the temporal bone treated with calcitonin. Otol Neurotol. 2006;27:999-1002. [CrossRef] [PubMed] [Google Scholar]
  21. de Lange J, van den Akker HP, Scholtemeijer M. Cherubism treated with calcitonin: report of a case. J Oral Maxillofac Surg 2007; 65:1665-1667. [CrossRef] [PubMed] [Google Scholar]
  22. Etoz OA, Dolanmaz D, Gunhan O. Treatment of cherubism with salmon calcitonin: a case report. Eur J Dent 2011;5:486-491. [PubMed] [Google Scholar]
  23. Lannon DA, Earley MJ. Cherubism and its charlatans. Br J Plast Surg 2001;54:708-711. [CrossRef] [PubMed] [Google Scholar]
  24. Pagnini I, Simonini G, Mortilla M, Giani T, Pascoli L, Cimaz R. Ineffectiveness of tumor necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism. Clin Exp Rheumatol 2011;29:147. [PubMed] [Google Scholar]
  25. Hero M, Suomalainen A, Hagström J, Stoor P, Kontio R, Alapulli H, et al. Anti-tumor necrosis factor treatment in cherubism–clinical, radiological and histological findings in two children. Bone 2013;52:347-353. [CrossRef] [PubMed] [Google Scholar]
  26. Kadlub N, Vazquez M-P, Galmiche L, L’Herminé AC, Dainese L, Ulinski T, et al. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism. J Bone Miner Res 2015;30:878-885. [CrossRef] [PubMed] [Google Scholar]
  27. Yoshitaka T, Kittaka M, Ishida S, Mizuno N, Mukai T, Ueki Y. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice. Bone 2015;71:201-209. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.